“Glioma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioma Market.

The Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Glioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Glioma treatment therapies with a considerable amount of success over the years. 
• Glioma companies working in the treatment market are Oncorus, Evgen Pharma, OncoSynergy, Inc., Eli Lilly and Company, Erasca, Inc., Chimerix, Agios Pharmaceuticals, Aadi Bioscience, Inc, SonALAsense, Ever Supreme Bio Technology, Day One Biopharmaceuticals, Bristol-Myers Squibb, Chimerix, and others, are developing therapies for the Glioma treatment 

• Emerging Glioma therapies in the different phases of clinical trials are- ONCR-719, SFX-01, OS2966, LY3410738, ERAS-801, ONC20, Ivosidenib, ABI-009, SONALA-001, ADCV-01, DAY101, Marizomib, ONC 201, and others are expected to have a significant impact on the Glioma market in the coming years.   
• In April 2023, Oblato, a division of HLB Therapeutics with headquarters in South Korea, has enrolled the first patient in the US for a Phase 1 trial of the oral formulation of OKN-007 for the treatment of recurrent high-grade glioma.
• In January 2021, ABI-009 (FYARROTM) will be developed and marketed in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan, under an exclusive licence arrangement announced by Aadi Bioscience and EOC Pharma (EOC), a prominent oncology specialist biopharmaceutical firm in China

Glioma Overview

A typical form of tumour with brain origins is the glioma. Gliomas, which begin in the glial cells that surround and support neurons in the brain, such as astrocytes, oligodendrocytes, and ependymal cells, account for about 33 percent of all brain tumours.Because they develop within the brain’s material and frequently mash with healthy brain tissue, gliomas are sometimes known as intra-axial brain tumours.

Get a Free Sample PDF Report to know more about Glioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioma-pipeline-insight

Emerging Glioma Drugs Under Different Phases of Clinical Development Include:

• ONCR-719: Oncorus
• SFX-01: Evgen Pharma
• OS2966: OncoSynergy, Inc.
• LY3410738: Eli Lilly and Company
• ERAS-801: Erasca, Inc.
• ONC206: Chimerix
• Ivosidenib: Agios Pharmaceuticals
• ABI-009: Aadi Bioscience, Inc
• Tofacitinib: Pfizer
• Enzastaurin: Denovo BioPharma
• MDNA55: Medicenna Therapeutics, Inc.
• Sym004: Symphogen A/S
• MN-166: MediciNova
• SONALA-001: SonALAsense
• ADCV-01: Ever Supreme Bio Technology
• DAY101: Day One Biopharmaceuticals
• Marizomib: Bristol-Myers Squibb
• ONC 201: Chimerix

Route of Administration

Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal antibody
• Small molecule
• Peptide

Glioma Pipeline Therapeutics Assessment

• Glioma Assessment by Product Type
• Glioma By Stage and Product Type
• Glioma Assessment by Route of Administration
• Glioma By Stage and Route of Administration
• Glioma Assessment by Molecule Type
• Glioma by Stage and Molecule Type

DelveInsight’s Glioma Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioma product details are provided in the report. Download the Glioma pipeline report to learn more about the emerging Glioma therapies

Some of the key companies in the Glioma Therapeutics Market include:

Key companies developing therapies for Glioma are – Bristol-Myers Squibb Co, Novartis AG, Merck & Co Inc, Pfizer Inc, Immunomic Therapeutics Inc, and others.

Glioma Pipeline Analysis:

The Glioma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment.
• Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioma drugs and therapies

Glioma Pipeline Market Drivers

• Rise in prevalence of Glioma, targeted therapy approach to improve the effectiveness of glioma treatment, robust Pipeline for Glioma are some of the important factors that are fueling the Glioma Market.

Glioma Pipeline Market Barriers

• However, poor prognosis and high rate of recurrence, drug resistance in glioblastoma and other factors are creating obstacles in the Glioma Market growth.

Scope of Glioma Pipeline Drug Insight    

• Coverage: Global
• Key Glioma Companies: Oncorus, Evgen Pharma, OncoSynergy, Inc., Eli Lilly and Company, Erasca, Inc., Chimerix, Agios Pharmaceuticals, Aadi Bioscience, Inc, SonALAsense, Ever Supreme Bio Technology, Day One Biopharmaceuticals, Bristol-Myers Squibb, Chimerix, and others
• Key Glioma Therapies: ONCR-719, SFX-01, OS2966, LY3410738, ERAS-801, ONC20, Ivosidenib, ABI-009, SONALA-001, ADCV-01, DAY101, Marizomib, ONC 201, and others
• Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies
• Glioma Market Dynamics: Glioma market drivers and Glioma market barriers 

Request for Sample PDF Report for Glioma Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services